Graves病131I治疗前后Ghrelin及胰岛素样生长因子-1的变化及临床意义

Abstract
Figure/Table
References (15)
Related Citation (4)

Download: PDF (0 KB) HTML (35 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the change and clinical significance of Ghrelin and insulin like growth factor-1（IGF-1）in patientswith Graves disease before and after treatmentwith different doses of131I.Methods 54 cases patientswith Graves disease and 40 cases of healthy physical examination from January 2013 to December were selected.The patients with Graves disease were divided into the low dose group and the high dose group，27 cases in each group.The healthy persons were selected as the control group.The patients in the low dose group were treated with131I of 2.60-2.95 MBq/g，while the patients in the high dose group were given131Iof 3.69-4.41 MBq/g treatment.The serum Ghrelin and IGF-1 level and serum FT3，FT4，TSH content before and after treatment in the two groups was compared.The incidence rate of hypothyroidism and recurrence rate in the two groupswas recorded.Results The level of FT3，FT4，IGF-1before treatment in the low dose group and the high dose group was higher than that in the control group，the level of TSH，Ghrelin before treatment in the low dose group and the high dose group was lower than that in the control group，with significant difference（P＜0.05）.The level of FT3，FT4，IGF-1 after treatment in the low dose group was lower than tha in the high dose group after treatment，the level of the TSH，Ghrelin after treatment in the low dose group was higher than that in the high dose group after treatment，with significant difference（P＜0.05）.The result of Person correlation analysis showed that the expression of Ghrelin and IGF-1 was negatively correlated with expression in patientswith Grave disease（r=-0.548，P＜0.05）.There was no significant difference in the incidence rate of hypothyroidism between the two groups（P＞0.05）.The recurrence rate in the low dose group was lower than that in the higher dose group，with significant difference（P＜0.05）.Conclusion Low dose131I in the treatment of Graves disease is effective and accurate，and the recurrence rate is low.It isworth recommending.

Key words： 131I Graves disease Ghrelin Insulin like growth factor-1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HE Jian
	CHEN Qiu

Cite this article:

HE Jian,CHEN Qiu. Change and clinical significance of Ghrelin and IGF-1 in patients w ith Graves disease before and after131I treatment[J]. 中国当代医药, 2016, 23(20): 60-62.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2016/V23/I20/60

［1］	杨金，刘子太，朱琳.小剂量131I治疗124例甲状腺功能亢进的临床疗效观察［J］.当代医学，2013，19（8）：145-146.
［3］	胡长军，崔兆辉，陆卫平.甲状腺功能减退患者治疗前后血清ghrelin水平的变化［J］.南京医科大学学报·自然科学版，2010，30（11）：1662-1663.
［5］	马玲.低剂量131I对Graves病患者血清Ghrelin水平及相关血清学指标的影响研究［J］.重庆医学，2015，44（32）：4529-4531.
［6］	Benedini S，Codella R，Caumo A.Different circulating ghrelin responses to isoglucidic snack food in healthy individuals［J］.Horm Metab Res，2011，43（2）：135-140.
［7］	Bossowski A，Sawicka B，SzaleckiM，et al.Analysis of serum adiponectin，resistin and leptin levels in children and adolescentswith autoimmune thyroid disorders［J］.JPediatr EndocrinolMetab，2010，23（4）：369-377.
［8］	卢丽娜，时立新，张巧，等.不同甲状腺功能状态血清胃促生长素水平的变化［J］.中华内分泌代谢杂志，2010，26（2）：132-134.
［9］	Ruchala M，Gurgul E，Stangierski A.Individual plasma ghrelin changes in the same patients in hyperthyroid，hypothyroid and euthyroid state［J］.Peptides，2014，51（1）：31-34.
［10］	Emami A，Nazem R，Hedayati M.Is association between thyroid hormones and gut peptides，ghrelin and obestatin，able to suggest new regulatory relation between the HPT axis and gut［J］.Regul Pept，2014，189（1）：17-21.
［11］	钟霞，戴晓华，高聆，等.五岳抗甲丸辅助治疗Graves病的疗效及对血清IGF-I水平的影响［J］.山东医药，2008，48（8）：30-32.
［14］	王钰娇，何为民.胰岛素样生长因子-1在甲状腺相关眼病患者血清中的变化及其在眼眶脂肪细胞中的表达［J］.中华实验眼科杂志，2015，33（11）：1033-1036.
［2］	厉连福，黄东标，邱海鸯.甲亢及甲减患者治疗前后IGF-1、IL-6及IL-8检测的临床意义［J］.放射免疫学杂志，2012，25（1）：24-25.
［4］	陆永经.放射性131碘在甲状腺功能亢进治疗中的临床应用研究［J］.中国医药导刊，2013，15（4）：135-137.
［12］	Kumar S，Iyer S，Bauer H.A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in Graves′orbital fibroblasts：inhibition by an IGF-I receptor blocking antibody［J］Clin Endocrinol Metab，2012，97（5）：1681-1687.
［13］	王钰娇，何为民，陈俊，等.IGF-1R与TSHR在甲状腺相关眼病眼眶脂肪组织中作用［J］.中国实用眼科杂志，2015，33（8）：890-895.
［15］	Smith TJ.Potential role for bonemarrow-derived fibrocytes in the orbital fibroblast heterogeneity associated with thyroid-associated ophthalmopathy［J］.Clin Exp Immunol，2010，162（1）：24-31.